Archived

Feb 11 2020

Leadiant Biosciences is Conducting the Registry Study of Revcovi^® Treatment in Patients with ADA-SCID

By naleadiant Archived

Leadiant Biosciences, Inc. announced it is conducting the Registry Study of Revcovi^® (elapegademase-lvlr) injection 1.6 mg/ml Treatment in Patients with Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID).

Leadiant Biosciences is Conducting the Registry Study of Revcovi^® Treatment in Patients with ADA-SCID
Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi^Ⓡ
Leadiant Biosciences to Collaborate with National Institutes of Health on Therapy in Late-Stage Development for GNE Myopathy
Sigma-Tau Pharmaceuticals, Inc. Changes Name to Leadiant Biosciences, Inc. and Reaffirms its Commitment to Rare Disease Communities

Archives

February 2020
November 2018
August 2018
February 2017

Leadiant Biosciences, Inc.
9841 Washingtonian Blvd., Suite 500
Gaithersburg, MD 20878

The product information provided in this page is intended only for residents of the United States. The products discussed on this page may have different product labeling outside of the United States. The health information described in this page is provided for educational purposes only and is not intended to substitute discussions with a healthcare provider.

About Leadiant Biosciences, Inc.
Research and Development
Products
Healthcare Professionals
- Compliance
- Resources
Patients and Caregivers

News
Careers
Contact Us
Sitemap
Terms of Use
Cookies Policy
Privacy Policy

Leadiant Biosciences Ltd. (International)

Close Menu

About Leadiant Biosciences, Inc.
Research and Development
Products
Healthcare Professionals
- Compliance
- Resources
Patients and Caregivers

News
Careers
Contact Us
|
International
United States
Canada

About Leadiant Biosciences, Inc.
Research and Development
Products
Healthcare Professionals
Patients and Caregivers
News
Careers
- Benefits
- Back
Contact Us
International
Canada

You are now leaving the Leadiant Biosciences, Inc. U.S. website and entering the Leadiant Biosciences, Ltd. International website.

Continue Cancel

You are now leaving the Leadiant Biosciences, Inc. U.S. website and entering the Leadiant Biosciences Ltd. website.

Continue Cancel

You are now leaving the Leadiant Biosciences, Inc. U.S. website and entering the Leadiant Biosciences, Inc. Canada website. The information is intended for Canadian audiences only.

Continue Cancel

You are now leaving the Leadiant Biosciences, Inc. U.S. website and entering the Leadiant Biosciences S.p.A. (corporate) website.

Continue Cancel

Archived

Leadiant Biosciences is Conducting the Registry Study of Revcovi® Treatment in Patients with ADA-SCID

Recent Posts

Archives

You are now leaving the Leadiant Biosciences, Inc. U.S. website and entering the Leadiant Biosciences, Ltd. International website.

You are now leaving the Leadiant Biosciences, Inc. U.S. website and entering the Leadiant Biosciences Ltd. website.

You are now leaving the Leadiant Biosciences, Inc. U.S. website and entering the Leadiant Biosciences, Inc. Canada website. The information is intended for Canadian audiences only.

You are now leaving the Leadiant Biosciences, Inc. U.S. website and entering the Leadiant Biosciences S.p.A. (corporate) website.

Leadiant Biosciences is Conducting the Registry Study of Revcovi^® Treatment in Patients with ADA-SCID